Real-World Analysis of Clinical and Demographic Characteristics, Treatment Patterns, and Outcomes in Predominantly Older Patients with HR+/HER2− Metastatic Breast Cancer Receiving Abemaciclib in Routine Clinical Practice

• Главные авторы: Alistair Ring (Автор), Meghan Karuturi (Автор), Emily Nash Smyth (Автор), Tasneem Lokhandwala (Автор), Kristin M. Sheffield (Автор), Joanne Willey (Автор), Orsolya Lunacsek (Автор), Francisco Sapunar (Автор), Zhanglin Lin Cui (Автор), Anna D. Coutinho (Автор), Sarah Rybowski (Автор)
• Формат: ‌
• Опубликовано: Adis, Springer Healthcare, 2023-09-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Abstract Introduction Hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) is the most frequently diagnosed metastatic breast cancer (mBC) subtype. Combinations of endocrine therapy (ET) with cyclin-dependent kinase 4/6 inhibitors (CDK4 & 6is) improve outcome...